- Sanofi has signed a Letter of Intent (LOI) with Canada’s pan-Canadian Pharmaceutical Alliance (pCPA) for Dupixent across four additional indications: pediatric atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD).
- The agreement advances reimbursement discussions for eligible patients with moderate-to-severe atopic dermatitis and adults with prurigo nodularis whose conditions are inadequately controlled with topical prescription therapies.
- For respiratory diseases, the LOI covers adults with COPD characterized by elevated blood eosinophils despite standard inhaled therapy, and severe CRSwNP inadequately controlled by systemic corticosteroids and/or surgery.
- Sanofi will work with public payers to support patient access. The LOI marks progress toward reimbursement for Dupixent across these indications, addressing unmet needs in chronic inflammatory skin and respiratory diseases.
Takeaways:
The pCPA agreement expands Dupixent’s potential reimbursed reach in Canada across four additional indications, strengthening Sanofi and Regeneron’s franchise in inflammatory skin and respiratory diseases. Broader public coverage could support uptake, particularly in COPD, while final reimbursement terms, eligibility criteria and payer negotiations will determine access and commercial impact.
Source: CA Newswire
